RT Journal Article
SR Electronic
T1 Implementation of an in-house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2 N501Y variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.03.21250661
DO 10.1101/2021.02.03.21250661
A1 Marielle Bedotto
A1 Pierre-Edouard Fournier
A1 Linda Houhamdi
A1 Philippe Colson
A1 Didier Raoult
YR 2021
UL http://medrxiv.org/content/early/2021/02/11/2021.02.03.21250661.abstract
AB The SARS-CoV-2 pandemic has been associated with the emergence of several variants with a mutated spike glycoprotein that are of substantial concern regarding their transmissibility and ability to evade immune responses. This warrants implementing strategies for their detection and surveillance. We have set up an in-house one-step real-time reverse transcription-PCR (qPCR) assay that specifically detects SARS-CoV-2 spike N501Y variants. Our assay was positive for all 6 patients found spike N501Y-positive by genome sequencing. Ten cDNA samples for each of the 10 Marseille variants identified by genome sequencing and three nasopharyngeal samples of a spike N501Y-negative variant (Marseille-4) that predominates locally tested negative. All negative controls among which 5 SARS-CoV-2-negative nasopharyngeal samples tested negative. First use in the setting of diagnosis on 51 nasopharyngeal samples from SARS-CoV-2-positive but Marseille-4-negative patients showed positivity in 5 cases further confirmed by sequencing as from spike N501Y variant-infected patients. Thus, our in-house qPCR system was found reliable for the detection of the N501Y substitution and allowed estimating preliminarily that spike N501Y variant prevalence was 4% among SARS-CoV-2 diagnoses since January 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future program managed by the National Agency for Research (ANR), Mediterranee-Infection 10-IAHU-03 and was also supported by Region Provence Alpes Cote d Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et dInnovation Mutualisees Mediterranee Infection), FEDER PA 0000320 PRIMMI. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the ethics committee of the University Hospital Institute Mediterranee Infection, Marseille, France, with the registration number 2020-029.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData underlying the study are available from the corresponding author upon request.